LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $94.57 Average Target Price from Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have received a consensus recommendation of “Moderate Buy” from the nine brokerages that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $94.57.

Several analysts recently issued reports on LMAT shares. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Cantor Fitzgerald started coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 target price on the stock. Barrington Research upped their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Finally, Oppenheimer reiterated an “outperform” rating and set a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st.

LeMaitre Vascular Trading Up 1.4 %

Shares of LeMaitre Vascular stock opened at $92.63 on Monday. The stock has a market capitalization of $2.08 billion, a P/E ratio of 50.62, a PEG ratio of 2.47 and a beta of 0.93. The business’s fifty day moving average price is $97.76 and its 200 day moving average price is $90.27. LeMaitre Vascular has a twelve month low of $52.88 and a twelve month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $54.82 million during the quarter, compared to analysts’ expectations of $53.50 million. During the same quarter in the previous year, the business earned $0.33 EPS. The company’s revenue for the quarter was up 15.6% on a year-over-year basis. As a group, sell-side analysts predict that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, December 5th. Investors of record on Thursday, November 21st were issued a $0.16 dividend. The ex-dividend date of this dividend was Thursday, November 21st. This represents a $0.64 annualized dividend and a yield of 0.69%. LeMaitre Vascular’s dividend payout ratio is presently 34.97%.

Insider Buying and Selling at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 3,750 shares of the business’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the sale, the director now directly owns 2,278 shares of the company’s stock, valued at $231,148.66. The trade was a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 10.79% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of LMAT. Glenmede Trust Co. NA raised its position in shares of LeMaitre Vascular by 1.3% during the 3rd quarter. Glenmede Trust Co. NA now owns 10,512 shares of the medical instruments supplier’s stock worth $976,000 after purchasing an additional 136 shares during the period. Summit Global Investments increased its position in LeMaitre Vascular by 2.4% in the third quarter. Summit Global Investments now owns 6,192 shares of the medical instruments supplier’s stock worth $575,000 after buying an additional 146 shares during the period. NBC Securities Inc. lifted its stake in LeMaitre Vascular by 73.2% in the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 183 shares during the last quarter. GAMMA Investing LLC lifted its stake in LeMaitre Vascular by 34.3% in the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock valued at $68,000 after buying an additional 188 shares during the last quarter. Finally, MML Investors Services LLC boosted its holdings in shares of LeMaitre Vascular by 2.8% during the third quarter. MML Investors Services LLC now owns 7,107 shares of the medical instruments supplier’s stock valued at $660,000 after acquiring an additional 191 shares during the period. 84.64% of the stock is currently owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.